Jump Financial LLC Sells 52,755 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Jump Financial LLC reduced its stake in Arrowhead Pharmaceuticals by 37.4%, selling 52,755 shares, and now owns a total of 88,204 shares worth $1,124,000.
• Several institutional investors have adjusted their holdings, with Aberdeen Group plc increasing its stake by 138.4%, now owning 1,072,827 shares valued at $13,668,000.
• Analysts have diverse views on Arrowhead Pharmaceuticals, with target price estimates ranging from $17.00 to $80.00, and the stock currently holds an average rating of "Buy."

Jump Financial LLC trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 37.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,204 shares of the biotechnology company's stock after selling 52,755 shares during the quarter. Jump Financial LLC owned 0.06% of Arrowhead Pharmaceuticals worth $1,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of ARWR. GAMMA Investing LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,628 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $49,000. CWM LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after buying an additional 2,523 shares during the period. KBC Group NV lifted its holdings in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after buying an additional 2,132 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter valued at $133,000. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR traded up $0.20 during midday trading on Thursday, hitting $28.00. 3,360,784 shares of the company traded hands, compared to its average volume of 2,838,531. The firm has a 50 day moving average of $18.52 and a 200-day moving average of $16.20. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $29.34. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of -21.88 and a beta of 1.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same period in the previous year, the business earned ($1.38) earnings per share. On average, analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider owned 247,122 shares of the company's stock, valued at $6,178,050. This represents a 5.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 25,000 shares of company stock worth $575,000. 4.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Finally, Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of "Buy" and a consensus price target of $43.14.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.